A Phase II Randomized-double Blinded Placebo Controlled Window of Opportunity Trial Comparing Conjugated Estrogens/Bazedoxifene to Placebo in Women Undergoing Surgical Therapy for Ductal Carcinoma in Situ (DCIS)

Trial Profile

A Phase II Randomized-double Blinded Placebo Controlled Window of Opportunity Trial Comparing Conjugated Estrogens/Bazedoxifene to Placebo in Women Undergoing Surgical Therapy for Ductal Carcinoma in Situ (DCIS)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Jan 2017

At a glance

  • Drugs Conjugated estrogens/bazedoxifene (Primary)
  • Indications Breast cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 03 Jan 2017 Status changed from not yet recruiting to recruiting.
    • 01 Sep 2016 Planned initiation date changed from 1 Mar 2016 to 1 Sep 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top